Complications cardiovasculaires de l’interféron-alpha
- 1 December 2007
- journal article
- abstracts
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 31 (12) , 1081-1084
- https://doi.org/10.1016/s0399-8320(07)78339-2
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusPublished by Elsevier ,1998
- Incidence of electrocardiographic abnormalities during treatment with human leukocyte interferon-alfa in patients with chronic hepatitis C but without preexisting cardiovascular diseaseCurrent Therapeutic Research, 1998
- Idiopathic dilated cardiomyopathy: lack of association with hepatitis C virus infectionHeart, 1998
- Side effects of α interferon in chronic hepatitis CHepatology, 1997
- Interferon‐alpha does not cause significant cardiac dysfunction in patients with chronic active hepatitisLiver International, 1997
- Adverse Effects of Interferon on the Cardiovascular System in Patients with Chronic Hepatitis C.Japanese Heart Journal, 1996
- Interferon Inhibits Cardiac Cell Function in VitroExperimental Biology and Medicine, 1981
- Common pathways of interferon and hormonal actionNature, 1980